These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 26954367)

  • 1. Evaluation of Tumor Cell Proliferation by Ki-67 Expression and Mitotic Count in Lymph Node Metastases from Breast Cancer.
    Aziz S; Wik E; Knutsvik G; Klingen TA; Chen Y; Davidsen B; Aas H; Aas T; Akslen LA
    PLoS One; 2016; 11(3):e0150979. PubMed ID: 26954367
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Correlation of proliferative index with various clinicopathologic prognostic parameters in primary breast carcinoma: A study from North India.
    Marwah N; Batra A; Marwah S; Gupta V; Shakya S; Sen R
    J Cancer Res Ther; 2018; 14(3):537-542. PubMed ID: 29893312
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Does analysis of biomarkers in tumor cells in lymph node metastases give additional prognostic information in primary breast cancer?
    Falck AK; Fernö M; Bendahl PO; Rydén L
    World J Surg; 2010 Jul; 34(7):1434-41. PubMed ID: 20213203
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Correlation of Conventional Ultrasound Characteristics of Breast Tumors With Axillary Lymph Node Metastasis and Ki-67 Expression in Patients With Breast Cancer.
    Zhang H; Sui X; Zhou S; Hu L; Huang X
    J Ultrasound Med; 2019 Jul; 38(7):1833-1840. PubMed ID: 30480840
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of mitotic index, in vitro bromodeoxyuridine labeling, and MIB-1 assays to quantitate proliferation in breast cancer.
    Thor AD; Liu S; Moore DH; Edgerton SM
    J Clin Oncol; 1999 Feb; 17(2):470-7. PubMed ID: 10080587
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic value of proliferation assay in the luminal, HER2-positive, and triple-negative biologic classes of breast cancer.
    Aleskandarany MA; Green AR; Benhasouna AA; Barros FF; Neal K; Reis-Filho JS; Ellis IO; Rakha EA
    Breast Cancer Res; 2012 Jan; 14(1):R3. PubMed ID: 22225836
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A standardized method for quantifying proliferation by Ki-67 and cyclin A immunohistochemistry in breast cancer.
    Mu K; Li L; Yang Q; Yun H; Kharaziha P; Ye DW; Auer G; Lagercrantz SB; Zetterberg A
    Ann Diagn Pathol; 2015 Aug; 19(4):243-8. PubMed ID: 26049669
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of the prognostic value of genomic grade index, Ki67 expression and mitotic activity index in early node-positive breast cancer patients.
    Bertucci F; Finetti P; Roche H; Le Doussal JM; Marisa L; Martin AL; Lacroix-Triki M; Blanc-Fournier C; Jacquemier J; Peyro-Saint-Paul H; Viens P; Sotiriou C; Birnbaum D; Penault-Llorca F
    Ann Oncol; 2013 Mar; 24(3):625-32. PubMed ID: 23117074
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of chemotherapy on Ki-67, Bcl-2 and Bak expression in primary tumors and lymph node metastases of breast cancer.
    Koda M; Sulkowska M; Kanczuga-Koda L; Tomaszewski J; Kucharczuk W; Lesniewicz T; Cymek S; Sulkowski S
    Oncol Rep; 2007 Jul; 18(1):113-9. PubMed ID: 17549355
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic value of Ki-67 in breast cancer patients with positive axillary lymph nodes: a retrospective cohort study.
    Li FY; Wu SG; Zhou J; Sun JY; Lin Q; Lin HX; Guan XX; He ZY
    PLoS One; 2014; 9(2):e87264. PubMed ID: 24498305
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Proliferation markers in breast carcinoma. Mitotic figure count, S-phase fraction, proliferating cell nuclear antigen, Ki-67 and MIB-1.
    Keshgegian AA; Cnaan A
    Am J Clin Pathol; 1995 Jul; 104(1):42-9. PubMed ID: 7611179
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ki-67 expression is superior to mitotic count and novel proliferation markers PHH3, MCM4 and mitosin as a prognostic factor in thick cutaneous melanoma.
    Ladstein RG; Bachmann IM; Straume O; Akslen LA
    BMC Cancer; 2010 Apr; 10():140. PubMed ID: 20398247
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Factors affecting sentinel lymph node metastasis in Turkish breast cancer patients: Predictive value of Ki-67 and the size of lymph node.
    Ozemir IA; Orhun K; Eren T; Baysal H; Sagiroglu J; Leblebici M; Ceyran AB; Alimoglu O
    Bratisl Lek Listy; 2016; 117(8):436-41. PubMed ID: 27546694
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nottingham-defined mitotic score: comparison with visual and image cytometric phosphohistone H3 labeling indices and correlation with Oncotype DX recurrence score.
    Zbytek B; Cohen C; Wang J; Page A; Williams DJ; Adams AL
    Appl Immunohistochem Mol Morphol; 2013 Jan; 21(1):48-53. PubMed ID: 22495373
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mib-1 proliferation index is an independent predictor of lymph node metastasis in invasive breast cancer: a prospective study on 675 patients.
    Marrelli D; Pinto E; Neri A; Megha T; Gioffrè W; Cioppa T; De Marco G; De Stefano A; Roviello F
    Oncol Rep; 2006 Feb; 15(2):425-9. PubMed ID: 16391864
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ki-67 expression in axillary lymph node metastases in breast cancer is prognostically significant.
    Tawfik K; Kimler BF; Davis MK; Fan F; Tawfik O
    Hum Pathol; 2013 Jan; 44(1):39-46. PubMed ID: 22939959
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High Ki-67 expression is a poor prognostic indicator of 5-year recurrence free survival in patients with invasive breast cancer.
    Yang XQ; Wang FB; Chen C; Peng CW; Zhang JF; Li Y
    Asian Pac J Cancer Prev; 2011; 12(11):3101-5. PubMed ID: 22393997
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumor-infiltrating lymphocytes, tumor characteristics, and recurrence in patients with early breast cancer.
    Kim ST; Jeong H; Woo OH; Seo JH; Kim A; Lee ES; Shin SW; Kim YH; Kim JS; Park KH
    Am J Clin Oncol; 2013 Jun; 36(3):224-31. PubMed ID: 22495453
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discordance of hormone receptor, human epidermal growth factor receptor-2, and Ki-67 between primary breast cancer and synchronous axillary lymph node metastasis.
    Kinoe H; Yamanouchi K; Kuba S; Morita M; Sakimura C; Kanetaka K; Takatsuki M; Abe K; Yano H; Matsumoto M; Otsubo R; Hayashida N; Nagayasu T; Eguchi S
    J BUON; 2018 Dec; 23(7):60-66. PubMed ID: 30722113
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FOXP3 expression is related to high Ki-67 index and poor prognosis in lymph node-positive breast cancer patients.
    Kim MH; Koo JS; Lee S
    Oncology; 2013; 85(2):128-36. PubMed ID: 23948758
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.